Skip to main content
HINOVA PHARMACEUTICALS INC. logo

HINOVA PHARMACEUTICALS INC. — Investor Relations & Filings

Ticker · 688302 ISIN · CNE1000059F5 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 393 across all filing types
Latest filing 2024-04-12 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688302

About HINOVA PHARMACEUTICALS INC.

https://www.hinovapharma.com/

Hinova Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of cancers and metabolic diseases. The company leverages its core technology platforms, including targeted protein degradation (PROTAC) and deuterium-based drug discovery, to develop a diverse pipeline of small molecule therapeutics. Its lead candidate, HC-1119 (deuterenzalutamide), is a next-generation androgen receptor antagonist currently in late-stage clinical development for metastatic castration-resistant prostate cancer. Other key programs include HP518, an orally bioavailable PROTAC degrader targeting the androgen receptor, and HP501, a selective URAT1 inhibitor designed for the treatment of hyperuricemia and gout. Hinova aims to address significant unmet medical needs through the development of high-quality, differentiated therapies for global markets.

Recent filings

Filing Released Lang Actions
中信证券股份有限公司关于海创药业股份有限公司2024年度关联交易预计的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from CITIC Securities regarding the expected related party transactions for the year 2024 of Haichuang Pharmaceutical Co., Ltd. It includes transaction amounts, related parties, approval procedures, and the sponsor's opinion on the transactions. The content focuses on the review and approval of related party transactions, which is a regulatory and compliance matter rather than a financial report or earnings release. The document is about the sponsor's verification opinion on related party transactions, which fits the category of Regulatory Filings (RNS) as it does not constitute a full audit report, annual report, or other specific financial filings. The document length is under 5,000 characters and contains detailed verification content, not just an announcement or certification letter, so it is not RPA or purely a certification. Therefore, the best classification is Regulatory Filings (RNS).
2024-04-12 Chinese
自愿披露HP501缓释片联合非布司他片进行原发性痛风伴高尿酸血症患者的临床试验获得药物临床试验批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a pharmaceutical company about receiving approval from the National Medical Products Administration (国家药品监督管理局) for clinical trials of a new drug. It details the drug's characteristics, clinical trial status, regulatory approval, and risk warnings. The document is an announcement of a regulatory approval event rather than a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial data. It is not a report publication announcement since it is not about publishing a report but about disclosing a regulatory approval event. Therefore, the best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2024-04-07 Chinese
关于首次公开发行战略配售限售股份上市流通的公告
Share Issue/Capital Change Classification · 95% confidence The document is an official announcement regarding the listing and circulation of restricted shares from the company's initial public offering (IPO) strategic placement. It details the number of shares becoming tradable, the lock-up period expiration, shareholder commitments, and includes verification from the sponsoring securities firm. The document is relatively short (2301 characters) and focuses on the announcement of the share listing event rather than providing financial statements or detailed financial data. It does not contain financial results, management discussion, or audit information. Therefore, it is best classified as a Share Issue/Capital Change announcement, specifically about the release of restricted shares into circulation after the IPO lock-up period.
2024-04-03 Chinese
中信证券股份有限公司关于海创药业股份有限公司首次公开发行战略配售限售股上市流通的核查意见
Regulatory Filings Classification · 95% confidence The document is a formal verification opinion from CITIC Securities regarding the listing and circulation of restricted shares from the initial public offering (IPO) of Haichuang Pharmaceutical Co., Ltd. It references regulatory approvals, share lock-up periods, and compliance with securities laws. The document is not a financial report, earnings release, or management discussion but rather a regulatory compliance and verification statement related to share circulation post-IPO. It does not announce voting results, board changes, or capital changes but focuses on the verification of restricted shares becoming tradable. This type of document fits best under Regulatory Filings (RNS) as it is a compliance and verification announcement without substantive financial data or report content.
2024-04-03 Chinese
2023年度业绩快报公告
Earnings Release Classification · 95% confidence The document is titled as a "2023 年度业绩快报公告" which translates to "2023 Annual Performance Express Report Announcement." It contains preliminary financial data for the year 2023, including revenue, profit, and asset figures, but explicitly states that the data is unaudited and preliminary, with final audited data to be disclosed in the full annual report. The document is relatively short (1634 characters) and serves as a brief announcement of preliminary financial results rather than a full detailed annual report. It does not contain comprehensive financial statements or detailed analysis typical of a full Annual Report (10-K). Therefore, this document fits the category of an Earnings Release (ER), which is an initial announcement of periodic financial results with key highlights only. FY 2023
2024-02-23 Chinese
自愿披露关于治疗血液系统恶性肿瘤的HP537片获得药物临床试验批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure announcement by a pharmaceutical company about receiving approval from the National Medical Products Administration (NMPA) for clinical trials of a new drug (HP537) targeting hematologic malignancies. It contains no financial data, no financial statements, no management discussion of financial results, and no regulatory certifications or filings related to financial performance. It is an announcement of a regulatory approval event related to drug development, not a financial report or management update. The document length is short (1640 characters), and it is clearly an announcement of a clinical trial approval, which is a regulatory event. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-02-22 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.